SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Munch-a-Biotech Today
An SI Board Since December 1998
Posts SubjectMarks Bans
3158 136 0
Emcee:  Biomaven Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2608As I recall, Structural Genomix had a pretty good reputation for quickly gettingBiotech Jim-7/9/2008
2607Lilly had a preexisting relationship with sgx on the structural side so that madrkrw-7/9/2008
2606kenhott says; <i>So it is probably more about their tech than their drugs.Steve Lokness-7/9/2008
2605Trading for a few cents above $3. Someone must think a counter offer is possiblerkrw-7/9/2008
2604Let's not forget sgx first two Bcr-abl attempts killed monkeys. But I would rkrw-7/9/2008
2603Vacations are for wimps. :) SGX had a kidney problem with their cMET lead candkenhott-7/9/2008
2602<i>Are there programs that make it unlikely someone else will sniff here?&DewDiligence_on_SI-7/8/2008
2601<i>You were right the first time: it’s $3.00 (not $3.10).</i> MightSteve Lokness-7/8/2008
2600<i>Edit: Make that 64 million in cash, or about $3.10/share.</i> YoDewDiligence_on_SI-7/8/2008
2599Table of Recent Biotech Buyouts at a Large Premium: siliconinvestor.comDewDiligence_on_SI-7/8/2008
2598Wilder will be happy when he returns from his vacation, I think he bought after rkrw-7/8/2008
2597You be too fast. :) edit: Hey wilder, no more SGXP to kick sand on any more.kenhott-7/8/2008
2596Lilly takes out SGX (SGXP) for $3 cash, about a 110% premium to the closing prictuck-7/8/2008
2595Shire Offers Euro 6.25 Per Share and Further Subscribes For Shares in a Capital kenhott-7/3/2008
2594Tongjitang management can't get the deal done due to credit market problems.tuck-6/30/2008
2593AstraZeneca Loses Key Biotech Talent CEO, Research Chief Of MedImmune Unit GeDoc Bones-6/27/2008
2592Barrier therapeutics picked off the bottom by Stiefel: >>Barrier Therapeutuck-6/23/2008
2591Sanofi plans $2.6 billion counterbid for Zentiva Wednesday June 18, 6:01 am ET Doc Bones-6/18/2008
2590fiercebiotech.com Boehringer Ingelheim to acquire Actimis Pharmaceuticals June scaram(o)uche-6/17/2008
2589Invitrogen, Applied Biosystems Join Forces in $6.7B Merger By Donna Young [Biowsim1-6/12/2008
2588Thought never crossed my mind, just don't know how close to tox mtx doses miscaram(o)uche-6/12/2008
2587medium munch; Not much of a premium but nice move by TWTI recently helps. MightSteve Lokness-6/9/2008
2586Tiny munch: Message 24659663sjemmeri-6/9/2008
2585Ipsen to Acquire Tercica Wednesday June 4, 9:00 pm ET -- $9.00 per Share to Be Pkenhott-6/5/2008
25848:39AM Kosan Biosciences: Bristol-Myers Squibb confirms to acquire Kosan BioscieIan@SI-5/29/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News